Logo

BGI Offer for Complete Genomics Extended Until March 1

Feb 25, 2013 | staff reporter

NEW YORK (GenomeWeb News) – BGI said after the close of the market on Friday it has again extended its cash tender offer for Complete Genomics.

The $118 million deal is now set to expire at midnight ET on March 1. The offer has been pushed back several times and most recently was to expire at midnight Feb. 22.

The depositary for the offer indicated that as of the close of business on Friday, more than 30.8 million shares, or 87 percent, of Complete Genomics' common stock had been validly tendered and not withdrawn.

BGI did not provide a reason for the extension but previously said that it is awaiting approval from China's Ministry of Commerce and the State Administration of Foreign Exchange.

Filed under

Clinical Sequencing
Sequencing
Diagnostics
Business News
BGI
mergers & acquisitions
Next-Generation Sequencing
MGI Tech
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.